ArticleMolecular genetics and metabolism reports2026

A 53-week, open-label phase IIIb study of velaglucerase alfa in Chinese patients with type 1 Gaucher disease: Safety, efficacy, and pharmacokinetics.

Lihui Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.